EUVIMEDEUVIMED entdecken
Crossref

TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer

Deo Rei L Agnila, Rahul Jain, Michael J Diaz, Tabitha R Hudlock, Rachel A Eakins, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck

Mammalian Genome · 2025

DOI: 10.1007/s00335-025-10127-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mammalian Genome, 2025. Verfasst von Deo Rei L Agnila und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Complementarity Determining Regions, Receptors, Antigen, T-Cell, Epitopes, T-Lymphocyte. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the fact that HPV vaccines are likely to lead to a significant reduction in cervical cancer occurrence, there remains cervical cancer incidence independent of the vaccine and cervical cancer arising in the absence of vaccination. Thus, continued efforts are needed to address the potential parameters of cervical cancer that could impact therapy and could lead to additional ways of reducing cervical cancer death rates. Adaptive immune receptor recombinations were obtained from the cancer genome atlas (TCGA) cervical cancer database through tumor exome and RNAseq files as well as from the independent Cancer Genome Characterization Initiative (CGCI) cervical cancer dataset. T-cell receptor (TCR) complementarity determining region-3's (CDR3s) were then assessed, based on chemical complementarity to human papillomavirus (HPV) T-cell epitopes. Results indicated increased overall survival probabilities consistently across the three TCR datasets with TCR CDR3 chemical complementarity to the same HPV epitopes, specifically immune epitope database (IEDB) designations: IEDB-1625373, IEDB-174148, and IEDB-110943. Among other potential applications of these results, the results may indicate HPV epitopes that could be useful targets for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsComplementarity Determining RegionsReceptors, Antigen, T-CellEpitopes, T-LymphocytePapillomaviridaePapillomavirus InfectionsHumansFemale

Stichwörter der Autor:innen

Adaptivematch.comCDR3-epitope chemical complementarityCervical cancerHPVT-cell receptors

Substanzen

Complementarity Determining RegionsReceptors, Antigen, T-CellEpitopes, T-Lymphocyte

Autor:innen und Institutionen

  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
  • Department of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
  • Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA. gblanck@usf.edu.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA. gblanck@usf.edu.
  • , 12901 Bruce B. Downs Blvd MDC7, Tampa, FL, 33612, USA. gblanck@usf.edu.

Zitieren

APA

Agnila, D. R. L., Jain, R., Diaz, M. J., Hudlock, T. R., Eakins, R. A., Chobrutskiy, A., Chobrutskiy, B. I., & Blanck, G. (2025). TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer. Mammalian Genome. https://doi.org/10.1007/s00335-025-10127-x

Vancouver

Agnila DRL, Jain R, Diaz MJ, Hudlock TR, Eakins RA, Chobrutskiy A, et al. TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer. Mammalian Genome. 2025. doi:10.1007/s00335-025-10127-x

BibTeX
@article{Agnila2025,
  author = {Agnila, Deo Rei L and Jain, Rahul and Diaz, Michael J and Hudlock, Tabitha R and Eakins, Rachel A and Chobrutskiy, Andrea and Chobrutskiy, Boris I and Blanck, George},
  title = {TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer},
  journal = {Mammalian Genome},
  year = {2025},
  doi = {10.1007/s00335-025-10127-x}
}
Kostenlos starten →